Pomerantz Law Firm Opens Investor Investigation Into TriSalus Life Sciences

Pomerantz LLP announced on June 18, 2026, that it is investigating claims on behalf of investors of TriSalus Life Sciences Inc., the Nasdaq-listed company trading under the ticker TLSI. The New York-based law firm advised investors in TriSalus to contact the firm to learn more about their potential rights and remedies.

The Investigation

The inquiry was disclosed by Pomerantz LLP, a firm that specialises in securities class action litigation. The announcement identified Danielle Peyton as the point of contact for investors seeking information, reachable at [email protected] or by telephone at 646-581-9980, extension 7980. The release offered no further detail on the specific nature of the claims under review or the time period to which the investigation relates.

What Investors Should Know

For shareholders in TriSalus Life Sciences, the disclosure of a formal legal investigation by a securities litigation firm is a development that typically warrants close attention. Investors who believe they may have suffered losses in connection with their holdings in TLSI are directed to reach out to Pomerantz LLP directly using the contact information provided. The firm's announcement did not specify a deadline for investors to respond, nor did it disclose the scope or current stage of the investigation.

Source Is Limited — What Remains Unknown

The source material released by Pomerantz LLP on June 18, 2026, provides only the fact of the investigation and contact details. No allegations have been enumerated, no dollar figures cited, no named defendants identified beyond the company itself, and no indication given of how many investors may be affected. NewsHK will report further developments as they become available.

---

TriSalus Life Sciences Inc. trades on Nasdaq under the symbol TLSI. Pomerantz LLP is headquartered in New York. Investors with questions may contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.